Foghorn Therapeutics Inc [FHTX] stock prices are down -4.14% to $6.02 at the moment. An important factor to consider is whether the stock is rising or falling in short-term value. The FHTX shares have gain 16.67% over the last week, with a monthly amount glided 34.38%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Foghorn Therapeutics Inc [NASDAQ: FHTX] stock has seen the most recent analyst activity on December 18, 2025, when BTIG Research initiated its Buy rating and assigned the stock a price target of $11. Previously, Guggenheim started tracking the stock with Buy rating on November 07, 2025, and set its price target to $12. Citizens JMP started tracking the stock assigning a Mkt Outperform rating and suggested a price target of $9 on April 23, 2025. B. Riley Securities initiated its recommendation with a Buy and recommended $10 as its price target on January 30, 2025. Jefferies started tracking with a Buy rating for this stock on September 03, 2024, and assigned it a price target of $18. In a note dated August 19, 2024, Evercore ISI initiated an Outperform rating and provided a target price of $20 on this stock.
The stock price of Foghorn Therapeutics Inc [FHTX] has been fluctuating between $2.94 and $6.95 over the past year. Currently, Wall Street analysts expect the stock to reach $11.5 within the next 12 months. Foghorn Therapeutics Inc [NASDAQ: FHTX] shares were valued at $6.02 at the most recent close of the market. An investor can expect a potential return of 91.03% based on the average FHTX price forecast.
Analyzing the FHTX fundamentals
The Foghorn Therapeutics Inc [NASDAQ:FHTX] reported sales of 24.52M for trailing twelve months, representing a surge of 4.42%. Gross Profit Margin for this corporation currently stands at 0.15% with Operating Profit Margin at -3.53%, Pretax Profit Margin comes in at -2.94%, and Net Profit Margin reading is -2.94%. To continue investigating profitability, this company’s Return on Assets is posted at -0.35, Equity is 1.05 and Total Capital is -0.72. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at -0.25.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance.
Ratios To Look Out For
It’s worth pointing out that Foghorn Therapeutics Inc [NASDAQ:FHTX]’s Current Ratio is 2.16. On the other hand, the Quick Ratio is 2.16, and the Cash Ratio is 1.05. Considering the valuation of this stock, the price to sales ratio is 14.38.
